Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Affinia Therapeutics logo — Building the next generation of gene therapies

Affinia Therapeutics

Building the next generation of gene therapies

Founded 2019 United States Waltham, United States 30 employees Series C Total: $210.00M Biotechnology, Health Care +2

General Information

Company Name Affinia Therapeutics
Founded Year 2019
Location United States Waltham, United States
Employees 30
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage Series C
Business Model B2B, B2D, Platform
Revenue Model Licensing, Product Sales, Service Fee
Social

BounceWatch is an independent company data service, not affiliated with Affinia Therapeutics. To contact Affinia Therapeutics, visit affiniatx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Affinia Therapeutics compare?

A PDF of Affinia Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Affinia Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Key Hire Nov 02, 2026

Affinia Therapeutics welcomes Ramsey Johnson as Vice President, Clinical Operations.

Event Participation Oct 30, 2026

Affinia Therapeutics participated in #HFSA26 with a poster, oral presentation, and symposium.

Affinia Therapeutics a competitor of yours? Have our desk watch it

About Affinia Therapeutics

Affinia Therapeutics, founded in 2019, is at the forefront of biotechnology, focusing on building the next generation of gene therapies. This United States-based company boasts a team with extensive experience in translating scientific discoveries into clinical realities, targeting the genetic roots of severe, rare, and prevalent diseases.

The company's mission centers on re-engineering adeno-associated virus serotype 9 (AAV9) to broaden the applicability of gene therapies beyond their current limitations. By addressing delivery challenges, Affinia Therapeutics aims to unlock novel therapeutic avenues for diseases affecting the heart and nervous system.

Having secured a recent $40.00 million Series C investment from an impressive roster of investors including Atlas Venture, F-Prime Capital, GV, among others, Affinia Therapeutics is poised to spearhead a transformative shift in treatment paradigms akin to breakthroughs witnessed in oncology.

Business keywords: gene therapy, AAV9 delivery, genetic medicines, rare diseases, central nervous system diseases, muscle diseases, synthetic biology, systems biology, high-throughput screening, capsid engineering, heart disease treatment, innovative vector design, therapeutic genetic payload, rational design

Services & Products

Development of gene therapies
Clinical trials for BAG3 DCM
AAV-based therapeutic solutions
Research and development in genetic diseases

Target Customers

Patients with rare genetic diseases Healthcare providers specializing in cardiology and neurology Research institutions focused on genetic medicine Biotechnology investors

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $40.00M 9
Atlas Venture F-Prime Capital GV
Atlas Venture, F-Prime Capital +7
01 Oct 2025
Series B $110.00M 11
Atlas Venture Casdin Capital F-Prime Capital
Atlas Venture, Casdin Capital +9
01 May 2021
Series A $60.00M 5
Atlas Venture F-Prime Capital Alexandria Venture Investments
Atlas Venture, F-Prime Capital +3
01 Mar 2020
Spinout Undisclosed 3
Harvard Ventures Ology Capital
Harvard Ventures, Ology Capital +1
01 Feb 2019

Affinia Therapeutics Alternatives & Competitors

View All Alternatives
Affinia Therapeutics vs
Taysha Gene Therapies
Taysha Gene Therapies United States

Taysha Gene Therapies is focused on advancing AAV-based gene therapies for severe monogenic diseases...

IPO
134 employees
Biotechnology, Life Sciences
Compare Affinia Therapeutics vs Taysha Gene Therapies
Affinia Therapeutics vs
AskBio Inc.
AskBio Inc. United States

Pioneering science to create transformative molecular medicines.

Grant
526 employees
Biopharma, Biotechnology
Compare Affinia Therapeutics vs AskBio Inc.
Affinia Therapeutics vs
MeiraGTx
MeiraGTx United Kingdom

Engineering Hope

IPO
419 employees
Biotechnology, Health Care
Compare Affinia Therapeutics vs MeiraGTx
Also compare with: Affinia Therapeutics vs Arbor Biotechnologies Arbor Biotechnologies Affinia Therapeutics vs StrideBio, Inc StrideBio, Inc View all alternatives

FAQ About Affinia Therapeutics

Building the next generation of gene therapies
Affinia Therapeutics was founded in 2019.
Affinia Therapeutics is headquartered in Waltham, United States.
Affinia Therapeutics operates in Biotechnology, Health Care, Health and Wellness and Life Sciences. Its work centres on gene therapy, AAV9 delivery, genetic medicines and rare diseases. Its customers include Patients with rare genetic diseases, Healthcare providers specializing in cardiology and neurology and Research institutions focused on genetic medicine.
Affinia Therapeutics has a B2B, B2D and Platform business model. Its revenue comes from Licensing, Product Sales and Service Fee.
Affinia Therapeutics has approximately 30 employees.
Affinia Therapeutics has completed 4 funding rounds, raising a total of $210.00M. The latest funding stage is Series C.
Affinia Therapeutics offers: Development of gene therapies, Clinical trials for BAG3 DCM, AAV-based therapeutic solutions, Research and development in genetic diseases.
Top alternatives and competitors to Affinia Therapeutics include Taysha Gene Therapies, AskBio Inc., MeiraGTx, Immusoft, Arbor Biotechnologies. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Affinia Therapeutics and Taysha Gene Therapies are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Affinia Therapeutics, https://bouncewatch.com/company/affinia-therapeutics, updated 6 November 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout